Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)

GlaxoSmithKline (GSK)

Status and phase: Completed; Phase 3

Conditions: Thrombosis, Venous

Treatments: Drug: Fondaparinux

Study type: Interventional

Funder types: Industry

Identifiers

NCT00320398

AR3106333

Details and patient eligibility

About

This study is requested by PMDA to confirm the optimal dose for THR (total hip replacement).

Enrollment: 114 patients

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients undergoing either an elective primary THR (total hip replacement) surgery or a revision of a THR.

Exclusion criteria

• Active, clinically significant bleeding (excluding drainage).